EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study

Ying Lin iD, Yunbo Yu, Zhihuang Hu iD, Chenchen Wei iD, Zezhou Wang iD, Yao Zhang, Zhenhua Wu, Bo Yu iD, Xinmin Zhao iD, Hui Yu, Xianghua Wu iD, Huijie Wang und 1 weitere

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Ying Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China. Hauptthemen laut MEDLINE: Paclitaxel, Carcinoma, Non-Small-Cell Lung, Bevacizumab, Albumins. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Collaborative Innovation Cluster Project of the Shanghai Municipal Commission of Health and Family Planning, Shanghai's 2022 "Science and Technology Innovation Action Plan" Special Project in Medical Innovation Research, Beijing Life Oasis Public Welfare Service Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective second‐line therapy is urgently needed for patients with driver‐gene‐negative non‐squamous non‐small cell lung cancer (nsqNSCLC) who progress after first‐line immunochemotherapy. This study aims to evaluate the efficacy and safety of bevacizumab combined with nab‐paclitaxel and platinum (the BAP regimen) in this setting.

Methods

This prospective, single‐arm, single‐centre study enrolled 56 patients with advanced driver‐gene‐negative nsqNSCLC failing first‐line immunochemotherapy. Patients received bevacizumab, nab‐paclitaxel, and platinum (carboplatin or cisplatin) for 4–6 cycles, followed by bevacizumab maintenance. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.

Results

All patients had failed first‐line platinum‐based immunochemotherapy. The confirmed ORR was 46.4% (26/56, 95% confidence interval [CI]: 34.0%–59.3%, p < 0.001), and DCR was 75%. The median PFS and OS were 5.6 (95% CI: 4.35–6.79) and 18.8 (95% CI: 10.31–27.24) months. Patients with ≤ 2 metastatic organs had a significantly longer median PFS than those with >2 metastatic organs ( p = 0.014). Multivariable Cox analysis showed that a platinum‐free interval

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelCarcinoma, Non-Small-Cell LungBevacizumabAlbuminsLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPlatinumHumansMaleFemaleProspective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

TWEAKbevacizumabnab‐paclitaxelnon‐squamous non‐small cell lung cancerplatinum re‐challengesecond‐line therapy

Substanzen

PaclitaxelBevacizumabAlbumins130-nm albumin-bound paclitaxelPlatinum

Autor:innen und Institutionen

  • Department of Medical Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Cancer Prevention, Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Shanghai Municipal Hospital Oncological Specialist Alliance, Shanghai, China.
  • Institute of Thoracic Oncology, Fudan University, Shanghai, China.

ORCID-Profile: Ying Lin, Zhihuang Hu, Chenchen Wei, Zezhou Wang, Bo Yu, Xinmin Zhao, Xianghua Wu, Jialei Wang

Förderung

  • Collaborative Innovation Cluster Project of the Shanghai Municipal Commission of Health and Family Planning
  • Shanghai's 2022 "Science and Technology Innovation Action Plan" Special Project in Medical Innovation Research
  • Beijing Life Oasis Public Welfare Service Centre

Zitieren

APA

Lin, Y., Yu, Y., Hu, Z., Wei, C., Wang, Z., Zhang, Y., Wu, Z., Yu, B., Zhao, X., Yu, H., Wu, X., Wang, H., & Wang, J. (2026). Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70814

Vancouver

Lin Y, Yu Y, Hu Z, Wei C, Wang Z, Zhang Y, et al. Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70814

BibTeX
@article{Lin2026,
  author = {Lin, Ying and Yu, Yunbo and Hu, Zhihuang and Wei, Chenchen and Wang, Zezhou and Zhang, Yao and Wu, Zhenhua and Yu, Bo and Zhao, Xinmin and Yu, Hui and Wu, Xianghua and Wang, Huijie and Wang, Jialei},
  title = {Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70814}
}
Kostenlos starten →